GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lineage Cell Therapeutics Inc (XTAE:LCTX) » Definitions » PS Ratio

Lineage Cell Therapeutics (XTAE:LCTX) PS Ratio : 23.26 (As of May. 16, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Lineage Cell Therapeutics PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Lineage Cell Therapeutics's share price is ₪3.931. Lineage Cell Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was ₪0.17. Hence, Lineage Cell Therapeutics's PS Ratio for today is 23.26.

The historical rank and industry rank for Lineage Cell Therapeutics's PS Ratio or its related term are showing as below:

XTAE:LCTX' s PS Ratio Range Over the Past 10 Years
Min: 13.05   Med: 100   Max: 600
Current: 23.7

During the past 13 years, Lineage Cell Therapeutics's highest PS Ratio was 600.00. The lowest was 13.05. And the median was 100.00.

XTAE:LCTX's PS Ratio is ranked worse than
68.5% of 1000 companies
in the Biotechnology industry
Industry Median: 9.125 vs XTAE:LCTX: 23.70

Lineage Cell Therapeutics's Revenue per Sharefor the three months ended in Mar. 2024 was ₪0.03. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was ₪0.17.

Warning Sign:

Lineage Cell Therapeutics Inc revenue per share is in decline over the past 12 months.

During the past 12 months, the average Revenue per Share Growth Rate of Lineage Cell Therapeutics was -34.30% per year. During the past 3 years, the average Revenue per Share Growth Rate was 118.30% per year. During the past 5 years, the average Revenue per Share Growth Rate was 57.20% per year. During the past 10 years, the average Revenue per Share Growth Rate was -0.10% per year.

During the past 13 years, Lineage Cell Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 118.30% per year. The lowest was -51.60% per year. And the median was -6.10% per year.

Back to Basics: PS Ratio


Lineage Cell Therapeutics PS Ratio Historical Data

The historical data trend for Lineage Cell Therapeutics's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lineage Cell Therapeutics PS Ratio Chart

Lineage Cell Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 89.00 352.00 102.08 13.45 20.96

Lineage Cell Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.43 22.74 23.14 20.96 32.17

Competitive Comparison of Lineage Cell Therapeutics's PS Ratio

For the Biotechnology subindustry, Lineage Cell Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lineage Cell Therapeutics's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lineage Cell Therapeutics's PS Ratio distribution charts can be found below:

* The bar in red indicates where Lineage Cell Therapeutics's PS Ratio falls into.



Lineage Cell Therapeutics PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Lineage Cell Therapeutics's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=3.931/0.169
=23.26

Lineage Cell Therapeutics's Share Price of today is ₪3.931.
Lineage Cell Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₪0.17.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Lineage Cell Therapeutics  (XTAE:LCTX) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Lineage Cell Therapeutics PS Ratio Related Terms

Thank you for viewing the detailed overview of Lineage Cell Therapeutics's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Lineage Cell Therapeutics (XTAE:LCTX) Business Description

Traded in Other Exchanges
Address
2173 Salk Avenue, Suite 200, Carlsbad, CA, USA, 92008
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cell transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

Lineage Cell Therapeutics (XTAE:LCTX) Headlines

From GuruFocus